A new study published in the Journal of American Society of Nephrology reveals that the risk of organ rejection and kidney failure is high among kidney transplant recipients who have low levels of preformed antibodies directed against the donated organs.
The findings could help clinicians provide better donor-recipient matches and tailor recipients'' immunosuppressive therapy after transplantation.
AdvertisementTransplant recipients who have had previous transplants, blood transfusions, and other sensitizing events often have antibodies directed against a particular donor''s kidney. These antibodies can increase the risk of organ rejection and kidney failure. But at what level do these antibodies put recipients at increased risk? Some newer tests, called solid phase assays, can detect them at much lower blood concentrations than traditional tests.
To investigate, Sumit Mohan, MD, Amudha Palanisamy, MD (Columbia University Medical Center) and their colleagues pored through the medical literature to find studies that looked at the health outcomes of kidney transplant recipients with such preformed donor-specific antibodies. Their search identified seven studies that included 1,119 patients.
Together, the results of these studies suggest that the detection of donor-specific antibodies by newer tests, despite negative results from older tests, nearly doubles the risk for antibody-mediated rejection and increases the risk of kidney failure by 76%. (The absolute risk of failure in the first year in the United States is currently about 8.2% for first-time recipients and about 10.7% for repeat transplant recipients.)
"Our study quantifies the level of risk associated with antibodies detected at the time of transplantation, helping clinicians better understand the prognosis and the risk of failure, thereby allowing for appropriate tailoring of immunosuppressive therapy," said Dr. Mohan. It also suggests that donor selection processes should take into consideration the presence of antibodies in the recipient, as identified by newer, more sensitive tests.
Study co-authors include Demetra Tsapepas, PharmD, Bekir Tanriover, MD, R. John Crew, MD, Geoffrey Dube, MD, Lloyd E Ratner, MD, David Cohen, MD, and Jai Radhakrishnan, MD.
Disclosures: The authors reported no financial disclosures.
The article, entitled "Donor-Specific Antibodies Adversely Impact Kidney Allograft Outcomes," will appear online at http://jasn.asnjournals.org/ on November 15, 2012, doi: 10.1681/2012070664.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Founded in 1966, and with more than 13,500 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.
# # #
P Optimizing Light Devices to Work More Efficiently With Human Brain can Save Billions of Dollars in Energy Costs After-Hours Email Being Frowned Upon by US Firms M
You May Also Like